Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755130 | 0.90 | KMO (0.44) | KMODHODHCD274PDCD1EIF4E | |
| SCHEMBL3747417 | 0.86 | ALDH1A1 (0.46) | DHODHCD274PDCD1NPSR1KDM4E | |
| SCHEMBL25459770 | 0.85 | LMNA (0.46) | KMOCD274PDCD1LG2 | |
| SCHEMBL3759586 | 0.84 | HTT (0.47) | DHODHCD274PDCD1KDM4EALDH1A1 | |
| SCHEMBL3755649 | 0.83 | DHODH (0.47) | KMODHODHCD274PDCD1EIF4E | |
| SCHEMBL3749641 | 0.83 | DHODH (0.45) | DHODHCD274PDCD1KDM4EALDH1A1 | |
| SCHEMBL3755033 | 0.82 | PDCD1 (0.46) | DHODHCD274PDCD1NPSR1KDM4E | |
| SCHEMBL3752403 | 0.82 | ADORA2A (0.41) | KMODHODHNPSR1 | |
| SCHEMBL23943225 | 0.82 | PLG (0.44) | DHODHCD274PDCD1KDM4EPDE10A | |
| SCHEMBL3752947 | 0.81 | ERN1 (0.45) | KMOCD274ALDH1A1HPGDPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | KMO 533/4885DHODH 1528/4885CD274 1943/4885 |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | KMO 1170/4885DHODH 501/4885CD274 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.